Skip to content
  • 中文
  • English
聯亞藥業聯亞藥業
    • About Us
      • Company Overview
      • Business Philosophy & Core Values
      • Key Milestones
      • Executive Leadership
      • Board of Directors
      • CSR & Sustainable Develpoment
    • R&D
      • Core Technology
      • Product Pipeline
      • Own-brand Products
    • Our Services
      • Facility & Capacities
      • CDMO Services
      • CMO Services
    • News & Events
      • Press Release
      • Media Coverage
      • Event
      • Lecture & Speech
    • Investors
      • Corporate Governance
      • Shareholder Services
      • Material Information
      • Investor Conference
    • Contact Us
      • Business Location
      • Business Liaison
      • Careers

News Activities

  • Press Release
  • Media Coverage
  • Event
  • Lecture & Speech

News Releases

Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound after Treatment Interruption

2019 年 4 月 18 日
Read More
« ← 頁面1 頁面2 → »

UBI Pharma Inc.

No.45, Guangfu N. Rd., Hukou Township, Hsinchu County 303036, Taiwan (R.O.C.)

  • Tel:+886-3-5977676
  • Fax:+886-3-5981173

Copyright © 2015 ALL RIGHT RESERVED.

  • About Us
    • Company Overview
    • Business Philosophy and Core Values
    • Key Milestones
    • Executive Leadership
    • Board of Directors
    • CSR & Sustainable Development
  • R&D
    • Core Technology
    • Products In Development
    • Product Introduction
  • Our Services
    • Facility & Capacities
    • CDMO Services
    • CMO Services
  • News & Events
    • Press Release
    • Media Coverage
    • Event
    • Lecture & Speech
  • Investors
    • Corporate Governance​
    • Shareholder Services
    • Material Information
    • Investor Conference
  • Contact Us
    • Business Locations​
    • Business Liaison
    • Careers
  • 中文

登入

忘記您的密碼?

註冊

您的個人數據將用於支持您在整個網站上的體驗,管理您帳戶的訪問權限以及我們的隱私權政策中描述的其他目的。